Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Micrus acquires rights to Genesis’s Catheter
The transaction includes an initial upfront payment, future development milestone payments and an undisclosed royalty on potential future products sales. The Genesis F A S T Funnel Catheter
The transaction includes an initial upfront payment, future development milestone payments and an undisclosed royalty on potential future products sales. The Genesis F A S T Funnel Catheter
The trial evaluated the safety and efficacy of combining a standard dose of Zevalin followed by high-dose Beam and autologous stem-cell transplantation (ASCT) in patients with non-Hodgkin’s lymphoma
L-DOS47 combines Helix’s proprietary DOS47 new drug candidate with a highly specific single domain antibody to form a potential new targeted drug product for the treatment of adenocarcinoma
The present work performed under a co-operative research and development agreement (CRADA) with the Department of Veteran’s Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota
This project builds on the progress of Galapagos’s July 2006 IWT funded project, where new biological models were developed to evaluate the effectiveness of small molecules to treat
Mark Mirken, president and COO of Millennium Biotechnologies, said: “Our agreement will allow us to use Millennium’s extensive clinical experience and success in the cancer and HIV channels
MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the
Although Merck spokesman Ron Rogers confirmed that a Fosamax-related deal has been signed, he did not divulge details about the deal, maintaining that the details were proprietary. Fosamax’s
Tyrima is a selective and reversible member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A (RIMA). The Phase I program evaluated a
This preliminary trial was conducted at the National Eye Institute (NEI), which is part of the US National Institute of Health (NIH). The trial, which examined the effect